Display options
Cite
Vanderwall DK, Woods GL, Weber JA, et al. Corpus luteal function in nonpregnant mares following intrauterine administration of prostaglandin E(2) or estradiol-17beta. Theriogenology. 1994;42(7):1069-83doi: 10.1016/0093-691x(94)90855-9.
Vanderwall, D. K., Woods, G. L., Weber, J. A., & Lichtenwalner, A. B. (1994). Corpus luteal function in nonpregnant mares following intrauterine administration of prostaglandin E(2) or estradiol-17beta. Theriogenology, 42(7), 1069-83. https://doi.org/10.1016/0093-691x(94)90855-9
Vanderwall, D K, et al. "Corpus luteal function in nonpregnant mares following intrauterine administration of prostaglandin E(2) or estradiol-17beta." Theriogenology vol. 42,7 (1994): 1069-83. doi: https://doi.org/10.1016/0093-691x(94)90855-9
Vanderwall DK, Woods GL, Weber JA, Lichtenwalner AB. Corpus luteal function in nonpregnant mares following intrauterine administration of prostaglandin E(2) or estradiol-17beta. Theriogenology. 1994;42(7):1069-83. doi: 10.1016/0093-691x(94)90855-9. PMID: 16727611.
Copy Download .nbib Format: NLM
Share it on

Theriogenology. 1994;42(7):1069-83. doi: 10.1016/0093-691x(94)90855-9.

Corpus luteal function in nonpregnant mares following intrauterine administration of prostaglandin E(2) or estradiol-17beta.

Theriogenology

D K Vanderwall, G L Woods, J A Weber, A B Lichtenwalner

Affiliations

  1. Northwest Equine Reproduction Laboratory Department of Animal and Veterinary Science University of Idaho, Moscow, ID 83844-2201 USA.

PMID: 16727611 DOI: 10.1016/0093-691x(94)90855-9

Abstract

The objective of this study was to test the hypothesis that intrauterine administration of prostaglandin E(2) (PGE(2)) or estradiol-17beta (E-17beta) would prolong CL function in nonpregnant mares. Nonpregnant mares were continuously infused with 240 mug/d of PGE(2), 6 mug/d of E-17beta, or vehicle (sham-treated) on Days 10 to 16 post ovulation (ovulation = Day 0), using osmotic minipumps surgically placed into the uterine lumen on Day 10 (n = 11 per group). Nonpregnant and pregnant mares served as negative and positive controls, respectively (n = 11 per group). Mares were defined as having prolonged CL function if plasma progesterone remained > 2.5 ng/ml and if ovulation did not occur on Days 9 to 30. Corpus luteal function was prolonged until Day 30 in 1 11 nonpregnant mares, 4 11 sham-treated mares, 6 11 E-17beta-treated mares, 8 11 PGE(2)-treated mares, and 11 11 pregnant mares. The incidence of prolonged CL function was similar (P=0.16) in the sham-treated and nonpregnant mares. The hypothesis that PGE(2) would prolong CL function in nonpregnant mares was supported, since the incidence of prolonged CL function was higher (P=0.003) in PGE(2)-treated versus nonpregnant mares, tended to be higher (P=0.09) in PGE(2)-versus sham-treated mares, and was not lower (P=0.11) in PGE(2)-treated versus pregnant mares. The hypothesis that E-17beta would prolong CL function in nonpregnant mares was not supported, since the incidence of prolonged CL function was not higher (P=0.34) in E-17beta-versus sham-treated mares, and was lower (P=0.02) in E-17beta-treated versus pregnant mares. These results demonstrate that intrauterine administration of a pharmacologic dose of PGE(2) initiated prolonged CL function in nonpregnant mares. Further experiments are needed to confirm the role of conceptus secretion of PGE(2) in CL maintenance, and to determine the mechanism of action of PGE(2) within the equine reproductive tract.

Publication Types